Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial

Due to the progressive decline in β-cell function, it is often necessary to utilize multiple agents with complementary mechanisms of action to address various facets and achieve glycemic control. Thus, this study aimed to evaluate the efficacy and safety of a fixed-dose combination (FDC) of metformi...

Full description

Saved in:

Bibliographic Details
Published in:	Clinical diabetes and endocrinology Vol. 10; no. 1; p. 3
Main Authors:	Aashish, Mondal, Arindam, Naskar, Siddiqi, Sheelu Shafiq, Bhosle, Deepak, Mallikarjuna, V J, Amol, Dange, Sanket, Sorate, Omkar, Gavali, Parth, Patel, Dhruvi, Hasnani, Durga, Prasad, Pradeep, Dalwadi, Suresh, Kumar, Vaishali, Pathak, Mayura, Chaudhari, Indraneel, Basu, Jayashri, Shembalkar, Arif, Fariooqui, Raghavendra, S K, Deepak, Varade, Ravindra, Thakkar, Shaishav, Bhanushali, Vijay, Gaikwad, Khan, Kamran, Mahajani, V V, Sharma, A D, Mayabhate, Mayur, Pawar, R R, Aiwale, A S, Vinayaka, Shahavi
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 10-02-2024 BioMed Central BMC
Subjects:	Antidiabetics Body weight Dextrose Diabetes Diabetes therapy Drug dosages Drug therapy, Combination Glucagon Glucose Glycosylated hemoglobin Hematology IMPACT study Insulin resistance Laboratories Medical research Medicine, Experimental Metformin Pioglitazone Sitagliptin Triple therapy Type 2 diabetes Type 2 diabetes mellitus India Sitagliptin IMPACT study Metformin Type 2 diabetes mellitus Triple therapy Pioglitazone
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!